DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for musculoskeletal system disease — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMusculoskeletal system disease maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for musculoskeletal system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
carbonic anhydrase 1 (CA1) — CA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet phenylsulfonyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7Q0D · 1.24 Å · ligand methyl 4-chloranyl-2-(phenylsulfonyl)-5-sulfamoyl-benzoate (84Z). Experimental structure, not a prediction.
What the evidence adds up to
A 2025 review summarises the role of bone morphogenetic protein (BMP) signalling in four musculoskeletal disorders: osteoporosis, osteoarthritis, rheumatoid arthritis, and sarcopenia. The review states that BMP signalling is expressed in nearly all organ systems and that it impedes the degeneration of musculoskeletal diseases. It concludes that targeting the BMP signalling pathway is a promising therapeutic approach and that investigating signalling cross talk could pave the way for effective treatments. No patient data, survival figures, or response rates are provided; the article is a narrative review of pathophysiological mechanisms.
A 2020 study examined the impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis. This was a nationwide population-based study, but the two supplemental files provided contain no numerical results, only metadata about the article. No efficacy data, response rates, or survival figures are available from these files.
A 2004 point of view piece from Dartmouth Medical School discusses funding sources for musculoskeletal disease research but contains no clinical data, drug information, or patient outcomes. A 2008 article on genome-wide association studies notes that most common musculoskeletal diseases show significant heritability and that few have treatments that prevent disease or induce true treatment-free remission. It states that genome-wide association studies have identified many genes involved in musculoskeletal disease pathogenesis but acknowledges that this approach will not identify all common disease genes and that other methods will be required.
What is still missing: no clinical trial has tested a BMP-targeting drug in these conditions with reported outcomes; the 2025 review is mechanistic only. The axial spondyloarthritis study has not released its primary results in the available material. Large-scale, hypothesis-free genetic discovery has not yet translated into treatments that prevent disease or produce drug-free remission. Funding for translational studies and properly stratified clinical trials remains the gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Orthopaedic Translation · 2025 · 5 citations · open access
Insights into the bone morphogenetic protein signaling in musculoskeletal disorders: Mechanisms and crosstalk
AbstractMusculoskeletal disorders are age-related illnesses that substantially impact the locomotor system. These problems can lead to serious complications, such as fractures, which can severely compromise the quality of life of patients. With the aging of the global population, the incidence and prevalence of musculoskeletal disorders are gradually increasing. Proliferation, differentiation, and cellular fate are extensively regulated by the BMP signaling pathway, which is expressed in approximately all organ systems. Musculoskeletal diseases are generally influenced by BMP signaling, which impedes the degeneration of musculoskeletal diseases. In this review, the pathophysiological functions of BMP signaling in four main musculoskeletal disorders (osteoporosis, osteoarthritis, rheumatoid arthritis, and sarcopenia) are summarized, and the role of cross talk between BMP signaling and other signaling pathways in the development of musculoskeletal disorders is reviewed. Finally, a conclusion regarding research on the role of BMP signaling in musculoskeletal disorders is formulated. Targeting the BMP signaling pathway is a promising therapeutic approach, and related studies have offered insights into the pathophysiological mechanism of musculoskeletal disorders. The Translational Potential of This Article: The identification of the BMP signaling pathway involved in the development of musculoskeletal disorders and the investigation of their signaling cross talk can pave the way for effective treatments and management strategies for patients with musculoskeletal disorders.
Sage Journals Data · 2020 · 0 citations · open access
sj-pdf-1-tab-10.1177_1759720X20972610 – Supplemental material for The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
AbstractSupplemental material, sj-pdf-1-tab-10.1177_1759720X20972610 for The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study by Imke Redeker, Britta Siegmund, Kamran Ghoreschi, Uwe Pleyer, Johanna Callhoff, Falk Hoffmann, Ursula Marschall, Hildrun Haibel, Joachim Sieper, Angela Zink and Denis Poddubnyy in Therapeutic Advances in Musculoskeletal Disease
sj-pdf-3-tab-10.1177_1759720X20972610 – Supplemental material for The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
AbstractSupplemental material, sj-pdf-3-tab-10.1177_1759720X20972610 for The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study by Imke Redeker, Britta Siegmund, Kamran Ghoreschi, Uwe Pleyer, Johanna Callhoff, Falk Hoffmann, Ursula Marschall, Hildrun Haibel, Joachim Sieper, Angela Zink and Denis Poddubnyy in Therapeutic Advances in Musculoskeletal Disease
AbstractFrom the Multidisciplinary Clinical Research Center in Musculoskeletal Diseases, Dartmouth Medical School, Lebanon, NH. The manuscript submitted does not contain information about medical device(s)/drug(s. Federal funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript Dr. Tosteson is supported in part by the National Institutes for Arthritis and Musculoskeletal Diseases (AR45444 and AR48094). Address correspondence and reprint requests to Anna Tosteson, ScD, HB7505, Clinical Research, One Medical Center Drive, Lebanon, NH 03756.
Genome-wide association studies and musculoskeletal diseases
AbstractBone and joint diseases are major causes of morbidity and mortality worldwide, and their prevalence is increasing as the average population age increases. Most common musculoskeletal diseases show significant heritability, and few have treatments that prevent disease or can induce true treatment-free, disease-free remission. Furthermore, despite valiant efforts of hypothesis-driven research, our understanding of the etiopathogenesis of these conditions is, with few exceptions, at best moderate. Therefore, there has been a long-standing interest in genetics research in musculoskeletal disease as a hypothesis-free method for investigating disease etiopathogenesis. Important contributions have been made through the identification of monogenic causes of disease, but the holy grail of human genetics research has been the identification of the genes responsible for common diseases. The development of genome-wide association (GWA) studies has revolutionized this field, and led to an explosion in the number of genes identified that are definitely involved in musculoskeletal disease pathogenesis. However, this approach will not identify all common disease genes, and although the current progress is exciting and proves the potential of this research discipline, other approaches will be required to identify many of the types of genetic variation likely to be involved.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
